NYKDO Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nykode Therapeutics AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 18.69 |
| 52 Week High | NOK 18.69 |
| 52 Week Low | NOK 18.69 |
| Beta | 1.44 |
| 1 Month Change | 0% |
| 3 Month Change | 1.49% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -30.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| NYKDO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -2.6% |
| 1Y | n/a | -24.5% | 2.4% |
Return vs Industry: Insufficient data to determine how NYKDO performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how NYKDO performed against the UK Market.
Price Volatility
| NYKDO volatility | |
|---|---|
| NYKDO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: NYKDO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NYKDO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 168 | Michael Engsig | nykode.com |
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10
Nykode Therapeutics AS Fundamentals Summary
| NYKDO fundamental statistics | |
|---|---|
| Market cap | NOK 5.75b |
| Earnings (TTM) | -NOK 449.25m |
| Revenue (TTM) | NOK 155.21m |
37.0x
P/S Ratio-12.8x
P/E RatioIs NYKDO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYKDO income statement (TTM) | |
|---|---|
| Revenue | US$14.52m |
| Cost of Revenue | US$0 |
| Gross Profit | US$14.52m |
| Other Expenses | US$56.54m |
| Earnings | -US$42.02m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 28, 2024
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -289.45% |
| Debt/Equity Ratio | 0% |
How did NYKDO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/06 00:08 |
| End of Day Share Price | 2023/11/09 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nykode Therapeutics AS is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Viktor Sundberg | ABG Sundal Collier Sponsored |
| Geir Holom | DNB Markets |
| Patrick Trucchio | H.C. Wainwright & Co. |